Despite its prevalence and wide clinical and prognostic impact, cardiovascular autonomic neuropathy (CAN) remains one of the most underdiagnosed and undertreated complications of diabetes mellitus.
Furthermore, the most recent evidence points to the clear need to guide and encourage clinicians, endocrinologists, cardiologists and diabetologists to familiarize themselves with the fact that early diagnosis of CAN is not only relevant and feasible in current clinical practice, but may also represent a unique therapeutic window to change the natural history of this disabling complication of diabetes mellitus.
But, first of all, we need to translate the methodology from clinical research to day by day medical practice and to standardize the best tests in terms of accuracy for early detection of CAN.
Despite its prevalence and wide clinical and prognostic impact, cardiovascular autonomic neuropathy (CAN) remains one of the most underdiagnosed and undertreated complications of diabetes mellitus.
Furthermore, the most recent evidence points to the clear need to guide and encourage clinicians, endocrinologists, cardiologists and diabetologists to familiarize themselves with the fact that early diagnosis of CAN is not only relevant and feasible in current clinical practice, but may also represent a unique therapeutic window to change the natural history of this disabling complication of diabetes mellitus.
But, first of all, we need to translate the methodology from clinical research to day by day medical practice and to standardize the best tests in terms of accuracy for early detection of CAN.